Apogee Therapeutics Inc. (NASDAQ: APGE) will report 16-week data from Part B of its Phase 2 APEX trial of zumilokibart ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE